Pfizer’s Lipitor (atorvastatin calcium) acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase. HMG Co-A reductase is a rate-limiting enzyme that converts HMG Co-A to mevalonate in the mevalonate pathway. This hepatic pathway is responsible for synthesizing various molecules, including cholesterol. The binding of Lipitor at the active site not only prevents substrate binding but also alters the enzyme’s conformation, preventing the attainment of a functional structure. The reduction in de novo cholesterol synthesis results in upregulation of low-density lipoprotein (LDL) receptors on hepatocytes, consequently increasing LDL endocytosis. Lipitor is also effective at treating homozygous familial hypercholesterolemia, despite the fact that LDL receptors are non-functional in patients with this disease. This is explained by Lipitor’s ability to limit cholesterol availability for the hepatic synthesis of lipoproteins containing apolipoprotein B, such as LDL.
Sales of Lipitor have declined as a result of competition from generic versions of the drug. Lipitor will experience further competition from generic versions of its major competitor, Crestor (rosuvastatin calcium; AstraZeneca/AbbVie/Shionogi), which entered the US market in May 2016. Pfizer has also recently given up on its efforts to switch Lipitor to an over-the-counter treatment, which will prevent the drug from recovering any revenues in the dyslipidemia market.
LIST OF FIGURES
9 Figure 1: Lipitor for dyslipidemia – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Lipitor for dyslipidemia
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Lipitor for dyslipidemia
13 Figure 4: Lipitor sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Lipitor drug profile
7 Table 2: Lipitor pivotal trial data in dyslipidemia
14 Table 3: Lipitor sales for dyslipidemia across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.